Vectura to present at J.P. Morgan Conference

Vectura Group plc

Vectura to present at the 36th Annual J.P. Morgan Healthcare Conference

2017 Pre-close trading update to be announced on Thursday 4th January 2018

Chippenham, UK - 20 December 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Company"), an industry-leading device and formulation business for inhaled airways products, today announced that James Ward-Lilley, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, 10 January 2018, at 9:30am PST / 17:30pm GMT.

A live webcast of the presentation and a copy of the slides will be available on the Company's website: http://www.vectura.com/investors/presentations-webcasts/. A recording will be available following the presentation.

Vectura will issue a 2017 pre-close trading update on Thursday 4th January 2018.

- Ends -

Enquiries

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. 

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, and Tianjin KingYork. 

For further information, please visit Vectura's website at www.vectura.com.